Sergio Davila

Sr. Director of Business Development at Acadia Pharmaceuticals

Speaker

Sergio is a results‑driven Business Development profession with deep expertise in the intersection of science, transactions, and strategy dedicated to unlocking innovation for patients. Over the course of his career, he has led and supported complex transactions across the full deal lifecycle—including sourcing, evaluation, financial valuation, deal structuring and negotiation, and post‑deal integration & alliance management—totaling approximately $50B in announced transaction value. He is currently a Senior Director of Business Development at Acadia Pharmaceuticals, where he plays a key role in executing deals across all stages of development to help build the CNS and rare disease pipeline.

Prior to Acadia, he held strategy and BD roles at Alexion Pharmaceuticals, where he contributed to major strategic transactions, in-licensing, and divestitures, ultimately through the AstraZeneca acquisition. Earlier in his career, he advised biopharmaceutical companies and life sciences investors at L.E.K. Consulting on growth strategy, portfolio decisions, and transaction evaluation. He holds a B.S. in Molecular Biology from UCLA and a Ph.D. in Microbiology and Immunobiology from Harvard University, where he was an NSF fellow.